Cohance Lifesciences Ltd · NSE:COHANCE
Cohance Lifesciences — Suven Pharmaceuticals — Q3 FY23 Earnings Presentation
23 slides from Cohance Lifesciences's earnings presentation, Jun 1, 2025
Slide 1: Suven Pharma Earnings Presentation Q3 & 9 months FY23
SUVEN PHARMA Earnings Presentation Q3 & 9 months FY23
Slide 2: Risk Statement
Risk Statement Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in
Slide 3: Table of Contents
4 14 Table of Operation & Financial Company Background Contents Performance Q3FY23 3
Slide 4: Operation & Financial Performance Q3FY23
Operation & Financial Performance Q3FY23 4
Slide 5: Businesswise data
Businesswise data CDMO Pharma CDMO Spec Chem Formulations & Other Ser vices 266.15 192.26 25.00 20.77 131.23 104.64 Q3FY22 Q3FY23 Q3FY22 Q3FY23 Q3FY22 Q3FY23 Note: Figures in INR Crore 5
Slide 6: Businesswise data
Businesswise data CDMO Pharma CDMO Spec Chem Formulations & Other 563.90 461.15 Ser vices 65.61 449.89 54.65 326.85 9MFY22 9MFY23 9MFY22 9MFY23 9MFY22 9MFY23 Note: Figures in INR Crore 6
Slide 7: Financial Snapshot
Financial Snapshot Q3FY23* 9MFY23 Growth in Growth in Growth in Revenue EBITDA PAT 25% 36.35% 38.70% -1.02% -7.05% -9.35% *Compared to previous quarter 7
Slide 8: Key Ratios
Key Ratios Q3FY23* 9MFY23 Growth in EBITDA to PAT to EBIT Income Income 39.88% 44.20% 30.32% -8.30% 44.25% 30.26% *Compared to previous quarter 8
Slide 9: Financials Q3FY23
Financials Q3FY23 Revenue EBIDTA PAT EPS 1,370 4,009 5.4 3,610 1,953 1,095 4.3 2,888 1,596 789 RUPEES MN RUPEES MN RUPEES MN 3.1 RUPEES 1,170 Q3FY22 Q2FY23 Q3FY23 Q3FY22 Q2FY23 Q3FY23 Q3FY22 Q2FY23 Q3FY23 Q3FY22 Q2FY23 Q3FY23 Note: Figures in INR Million 9
Slide 10: Financials 9MFY23
Financials 9MFY23 Revenue EBIDTA PAT EPS 10,098 9,995 4,758 4,422 3,336 13.1 3,024 RUPEES MN RUPEES MN RUPEES MN RUPEES 11.9 9MFY22 9MFY23 9MFY22 9MFY23 9MFY22 9MFY23 9MFY22 9MFY23 Note: Figures in INR Million 10
Slide 11: Financials Q3FY23
Financials Q3FY23 EBITDA Margin (%) PAT Margin (%) 49% 44% 41% 34% 30% 27% Q3FY22 Q2FY23 Q3FY23 Q3FY22 Q2FY23 Q3FY23 11
Slide 12: Financials 9MFY23
Financials 9MFY23 EBITDA Margin (%) PAT Margin (%) 47% 44% 33% 30% 9MFY22 9MFY23 9MFY22 9MFY23 12
Slide 13: Financial Snapshot – Q3 and 9 months FY23
Financial Snapshot – Q3 and 9 months FY23 Quarter ended Period ended Previous year 31-Dec-22 30-Sep-22 31-Dec-21 31-Dec-22 31-Dec-21 31-Mar-22 Revenue from operations 3,484.89 2,784.02 3,915.85 9,656.90 9,563.75 13,202.22 Other Income 125.11 103.89 92.74 337.97 533.92 1,877.88 Total income 3,610.00
Slide 14: Company Background
Company Background SUVEN 14 PHARMA
Slide 15: Business Model
Business Model Process Custom Research Synthesis Contract Development And Manufacturing Operations (CDMO) Formulation Clinical Development Supplies Mfg Analytical & & Packaging Services 15
Slide 16: Brief Profile
Brief Profile BUSINESS OVERVIEW KEY STRENGTHS o Integrated CDMO company with strong o Preferred global outsourcing FINANCIAL OVERVIEW capabilities right from partner with capabilities o Standalone Revenues, EBIT and PAT process research & across the entire CDMO of Rs 9995 Mn, Rs 4100 Mn and Rs devel
Slide 17: Overview
Overview Suven is an integrated Contract Development and Manufacturing Operations company Suven provides services to leading Global Life Science and Fine Chemical majors including Custom Synthesis, Process R&D, Scale Up and Contract Manufacturing of intermediates, APIs and formulations. Since our fo
Slide 18: Our Focus: NCE based CDMO
Our Focus NCE based A full-fledged bio- pharmaceutical solutions CDMO provider for global pharmaceutical companies 18 18
Slide 19: Financial Approach
Financial Approach Consistently Low dividend debt paying Shareholder Prudent value creation utilisation of focus cash flows 19
Slide 20: Business Drivers
Business Drivers Industry Relationship An integrated research service provider with Leveraging on unmatched capabilities Present across the research capabilities to delivering NCE entire CDMO value research chain – State of the art intermediates & facilities located APIs across India and US 20
Slide 21: Business Drivers
Business Drivers Execution Capabilities Over 85% of Working with revenues from innovator companies regulated in developed markets markets having stringent regulations – Long term reflection of our commercial supply research skills Repeat business with the launch of owing to long product by global st
Slide 22: Multi Location Facilities
Multi Location Facilities o o 300 CM reactors (93) 500L to 10 KL GL/SS o GMP Intermediates Vizag, Andhra Pashamylaram, Telangana, India Banjara Hills, Hyderabad, India Suryapet, Telangana, India Pradesh, India API & Formulation Facility Corporate Office Intermediate Mfg. Facility o 307 KL reactor vo
Slide 23: Contact
Contact For queries and requests, please contact: Sunder Venkatraman Suven Pharmaceuticals Ltd Suven Pharmaceuticals Ltd Tel: +91 939 248 3011 # 8-2-334, SDE Serene Chambers, Email: info@suvenpharm.com For more info: www.suvenpharm.com 3rd Floor, Road No. 5, Avenue - 7, Banjara Hills, Hyderabad-500
Suven Pharmaceuticals — Q3 FY23 Earnings Presentation on 6ix